Two new biomarkers for Alzheimer’s disease include one in the blood that relates to neurodegeneration and another that reflects blood–brain barrier dysfunction and is identifiable in cerebrospinal fluid analysis.
References
Preische, O. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0304-3 (2019).
Nation, D.A. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0297-y (2019).
Jansen, W. J. et al. JAMA Psychiatry 75, 84–95 (2018).
Ashton, N. J. et al. Biomark Med. 12, 799–812 (2018).
Fagan, A. M. et al. Sci. Transl. Med. 6, 226ra230 (2014).
Maia, L. F. et al. Sci. Transl. Med. 5, 194re192 (2013).
Sato, C. et al. Neuron 98, 861–864 (2018).
Okamura, N. et al. Clin. Transl. Imaging 6, 305–316 (2018).
Cummings, J., Lee, G., Ritter, A. & Zhong, K. Alzheimers Dement. (NY) 4, 195–214 (2018).
Rasmussen, M. K., Mestre, H. & Nedergaard, M. Lancet Neurol. 17, 1016–1024 (2018).
Khalil, M. et al. Nat. Rev. Neurol. 14, 577–589 (2018).
Bergman, J. et al. Neurol. Neuroimmunol. Neuroinflamm. 3, e271 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.Z. has served at scientific advisory boards of Roche Diagnostics, Wave, Samumed and CogRx and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures–based platform company at the University of Gothenburg. J.M.S. has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); has consulted for Roche, Eli Lilly, Biogen and Merck; received royalties from Oxford University Press and Henry Stewart Talks; given education lectures sponsored by Eli Lilly, Biogen and GE; and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE.
Rights and permissions
About this article
Cite this article
Zetterberg, H., Schott, J.M. Biomarkers for Alzheimer’s disease beyond amyloid and tau. Nat Med 25, 201–203 (2019). https://doi.org/10.1038/s41591-019-0348-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0348-z
- Springer Nature America, Inc.
This article is cited by
-
Recent Advances in Photoelectrochemical Sensing of Alzheimer’s Biomarkers
BioChip Journal (2023)
-
The trend of disruption in the functional brain network topology of Alzheimer’s disease
Scientific Reports (2022)
-
Biomarkers of Parkinson’s disease: 20 years later
Journal of Neural Transmission (2019)